The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2016 | The importance of anti-CD38 monoclonal antibodies for multiple myeloma
Rafael Fonseca, MD from the Mayo Clinic, Scottsdale, AZ discusses the importance of monoclonal antibodies for multiple myeloma (MM). At the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL, Prof. Fonseca discussed a Phase Ib trial of isatuximab plus lenalidomide and dexamethasone in relapsed/refractory MM presented by Dr Ravi Vij. Prof. Fonseca highlights the attention monoclonal antibodies, particulary those that target CD38, receive and mentions daratumumab and isatuximab as examples. According to Prof. Fonseca, it is becoming apparent that monoclonal antibodies combine very well and can achieve deep levels of responses.
